Dr. Weinstein is professor of medicine at Georgetown University Medical Center and Associate Chairman, Department of Medicine, and Director, Section of Rheumatology, at MedStar Washington Hospital Center. He is board certified in rheumatology and diagnostic immunology. He attended medical school at the University of Toronto and trained in internal medicine and rheumatology in Toronto and at the Hammersmith Hospital in London. Dr. Weinstein has held faculty positions at medical schools in Toronto and the United States and has been elected a Master of the American College of Rheumatology (MACR) and a Fellow of the Royal College of Physicians (FRCP) of the United Kingdom.

Dr. Weinstein's areas of interest include clinical, laboratory and treatment studies in SLE (Systemic Lupus Erythematosus), as well as Lyme disease, rheumatoid arthritis and connective tissue diseases. He has authored/co-authored over 100 clinical and research papers and chapters. Some of his earliest studies related to complement metabolism and the usefulness of complement in the diagnosis of SLE.

Dr. Weinstein has helped train more than 50 rheumatologists in the United States and abroad and has volunteered for many nonprofit organizations, including the American College of Rheumatology, Arthritis Foundation, Canadian Arthritis Society, National Institutes of Health, Centers for Disease Control and Prevention, and the Lupus Foundation of America (LFA). He has been involved in the formation and expansion of lupus clinics in many hospitals, has been chairman of the LFA-DC/MD/VA Medical Scientific Advisory Council and is currently co-chair of its board of directors. In 2008, Dr. Weinstein was recognized by the LFA as Volunteer of the Year.

"We are honored to have Dr. Weinstein on the board due to his extensive strategic and clinical experience in rheumatology and autoimmune disease," stated Ron Rocca, Exagen president and CEO. "With his valuable input, we will continue to develop meaningful clinical diagnostic tests to assist rheumatologists in improving patient outcomes."

About ExagenExagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the areas of rheumatology and autoimmune diseases. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information, please visit www.AviseTest.com.

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...